Join us as we delve into the pivotal role of Ly6 genes in cancer, fusing molecular insights with oncological understanding. Our research illuminates the intricate interplay between Ly6 genes and tumorigenesis, shedding light on potential diagnostic and therapeutic avenues. Collaborative efforts drive the translation of our findings into practical solutions, propelling advancements in cancer treatment and diagnosis. 

We use multidisciplinary approach to target Ly6 biomarkers in developing antibody and CAR-T technology focus on optimizing efficacy and safety via innovative antigen targeting and vector systems. By forging collaborations, we expedite scientific breakthroughs, offering new prospects against refractory cancers and reshaping the landscape of oncology. 

EVs are crucial drivers of intercellular communication, harboring bioactive payloads including protein, RNA, and DNA. EVs have recently been linked to cancer development, metastatic niche formation, and immune system modulation. We are seeking to further understand the biological underpinnings of how cancer-derived EVs propagate tumorigenesis, immunosuppression, and metastasis.